All latest stories
The European Commission is complementing the successful EU Vaccines Strategy with a strategy on COVID-19 therapeutics to support the development and availability of much-needed COVID-19 therapeutics, including for the treatment of ‘long COVID'.
Parliament adopted its negotiating position on the proposal for a certificate to reaffirm the right to free movement in Europe during the pandemic. MEPs agreed that the new “EU COVID-19 certificate” - instead of Digital Green Certificate, as proposed by the Commission - should be in place for 12 months and not longer.
At its meeting of 20 April 2021, EMA’s safety committee (PRAC) concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen. PRAC also concluded that these events should be listed as very rare side effects of the vaccine.
Once in place, the new measures will allow the Commission and other EU agencies and bodies to import and purchase goods and services VAT-free when those purchases are being distributed during an emergency response in the EU. The recipients might be Member States or third parties, such as national authorities or institutions (for example, a hospital, a national health or disaster response authority).
EU4Health will make a significant contribution to the post-COVID-19 recovery by making the EU population healthier, supporting the fight against cross-border health threats and boosting the EU's preparedness and capability to respond effectively to future health crisis, as part of a future strong European Health Union.
The European Commission has proposed to create a Digital Green Certificate to facilitate safe free movement inside the EU during the COVID-19 pandemic. The Digital Green Certificate will be a proof that a person has been vaccinated against COVID-19, received a negative test result or recovered from COVID-19.
During a busy plenary session MEPs marked International Women´s Day, adopted investment and health programmes and paved the way for the Conference on the Future of Europe.
The European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the fourth COVID-19 vaccine authorised in the EU.
MEPs adopted the EU4Health programme for 2021-2027, which aims to prepare EU health systems more rigorously for future health threats and pandemics.
The European Commission published its annual report on the Safety Gate, which is the EU rapid alert system for dangerous consumer products helping to take dangerous non-food products off the market.
To help EU consumers cut their energy bills and carbon footprint, a brand new version of the widely-recognised EU energy label will be applicable in all shops and online retailers from Monday, 1 March 2021.
To ensure that citizens can continue to enjoy roaming without additional charges when travelling in the EU, the Commission proposed a new Roaming Regulation. At a time when non-essential travel is discouraged, this is an important action in preparing a brighter future.
The European Commission has approved a second contract with the pharmaceutical company Moderna, which provides for an additional purchase of 300 million doses (150 million in 2021 and an option to purchase an additional 150 million in 2022) on behalf of all EU Member States.
The new European bio-defence preparedness plan against COVID-19 variants called “HERA Incubator” will work with researchers, biotech companies, manufacturers and public authorities in the EU and globally to detect new variants, provide incentives to develop new and adapted vaccines, speed up the approval process for these vaccines, and ensure scaling up of manufacturing capacities.
The EU must continue its concerted efforts to fight the COVID-19 pandemic and take urgent measures to ramp up vaccines production to meet citizens’ expectations, MEPs say.
The Commission presented its SAMIRA Action Plan – the Strategic Agenda for Medical Ionising Radiation Applications. The Plan will improve EU coordination, ensure that radiological and nuclear technologies continue to benefit the health of EU citizens, and contribute to the fight against cancer and other diseases.
On the eve of the World Cancer Day, the European Commission presented Europe's Beating Cancer Plan – a main priority in the area of health of the von der Leyen Commission and a key pillar of a strong European Health Union.
Following the renewed request from the European Commission on 27 January 2021, pharmaceutical company AstraZeneca has agreed to publish the redacted contract signed between the two parties on 27 August 2020. The Commission welcomes the company's commitment towards more transparency in its participation in the rollout of the EU Vaccines Strategy.